Adaptimmune reports progress on GSK-partnered immune-oncology candidate
This article was originally published in Scrip
Executive Summary
Adaptimmune, the UK biotech company which recently raised a $104m series A financing round from US investors, has released interim clinical data from a pilot trial of its T-cell therapy targeting the NY-ESO-1 antigen, a program partnered with GlaxoSmithKline, in the treatment of synovial sarcoma.